Rating Change
Barclays reiterated its Equal-Weight rating on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on August 18, 2026.
reiterateNASDAQ:AMPH
Barclays Reiterates Equal-Weight Rating on Amphastar Pharmaceuticals, Inc. (AMPH)
Barclays reiterated its Equal-Weight rating on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on August 18, 2026.
At publication ·
What changed
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) · reiterate
- Firm
- Barclays
- Rating
- Equal-Weight to Equal-Weight
- Price at event
- $21.80
- Market capitalization
- $929.6M
At a glance
Key takeaways
- Barclays reiterated an Equal-Weight rating on Amphastar Pharmaceuticals (AMPH) on August 18, 2026, indicating a neutral outlook on the stock.
Market Context
Amphastar Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $21.80 with a market capitalization of $929.6M. The stock has declined 30.9% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amphastar Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amphastar Pharmaceuticals, Inc.
Among the 10 most recent ratings: 0 Buy, 9 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | Barclays | Equal-Weight | N/A |
| Aug 07, 2026 | Wells Fargo | Equal-Weight | N/A |
| Aug 07, 2026 | Piper Sandler | Neutral | N/A |
| Jun 29, 2026 | B of A Securities | Underperform | N/A |
| Jun 03, 2026 | Barclays | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View AMPH Stock Page
Frequently Asked Questions
What does the Equal-Weight rating mean for AMPH?
A rating of Equal-Weight from Barclays reflects the analyst's outlook on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMPH forecast page.